NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT06122493 2023-11-08
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2 Recruiting
NCT02033538 2015-03-05
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Zhejiang University
Phase 2 Withdrawn